CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Withings ScanWatchWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug188 Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D011024 Pneumonia, Viral NIH 0.13
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Munich Remote SpO2 and Electrocardiogram Assessment in Covid-19 Patients

Covid-19, a commonly severe respiratory tract infection caused by the SARS-CoV2 Coronavirus, poses an increasing threat to individual health and health care systems. The individual disease course ranges from mild to life threatening, the pandemic spread leads to a shortage of health care resources including intensive care availability. It should be the overarching goal to allocate sparse health care resources to those most at need and to simultaneously avoid unnecessary blocking of resources by clinically unjustified hospitalizations. Individuals with preexisting cardiovascular conditions are at the highest risk of health deterioration, even at younger age. Objective criteria for hospitalization are not immediately available in a outpatient settings. Hence, hospitalization and emergency medical contact is often triggered by subjectively interpreted symptoms. The goal of this project is thus to improve the availability of objective measurements in the outpatient setting by means of an innovative, smartwatch mediated telemedicine approach. To achieve this goal, the investigators will conduct a randomized clinical trial comparing a smartwatch based telemedicine intervention with standard of care. The intervention group will receive regular objective measurements of heart rate, ECG, and SpO2 and will get access to a 24/7 medical care hotline for consultation. The investigators hypothesize that the intervention group will benefit by a significant reduction in unnecessary hospitalizations and unplanned emergency medicine contacts.

NCT04471636 Covid-19 Cardiovascular Risk Factor Device: Withings ScanWatch

Primary Outcomes

Description: Occurrence of any of the above during follow-up

Measure: Rate of participants with a combination of hospitalization and unplanned use of hospital emergency department or emergency medical service

Time: 30 days

Secondary Outcomes

Description: Occurrence of hospitalization during follow-up

Measure: Rate of participants hospitalized

Time: 30 days

Description: Occurrence of any of the above during follow-up

Measure: Rate of participants with unplanned use of hospital emergency department or emergency medical service

Time: 30 days

Description: Occurrence of death of any cause during follow-up

Measure: Rate of participants experiencing death of any cause

Time: 30 days

Description: Occurence of daeth of Covid-19 during follow-up

Measure: Rate of participants experiencing death of Covid-19

Time: 30 days


No related HPO nodes (Using clinical trials)